On August 21, GENSCRIPT BIO rose 3.18% in regular trading, trading at 34.32 HKD/share, with turnover of HKD 487 million. The stock continues its post-earnings rally as multiple institutions have issued upgraded target prices following strong first-half results.

BOCOM International maintained its Buy rating and raised its target price to 32.2 HKD, citing AI-driven drug discovery (AIDD) revenue surging over 105% year-over-year to approximately USD 40 million in 1H, with expectations for further acceleration in 2H. JPMorgan raised its target to 35 HKD, Huatai Securities maintained Buy with a target of 36.08 HKD, and CICC raised its target 78.8% to 32 HKD. The company reported 1H revenue of USD 404.2 million, up 27.3% year-over-year, with life sciences adjusted operating profit surging 102.8%. AIDD-related business doubled year-over-year for the third consecutive half-year period, and full-year guidance was raised to 25-30% revenue growth with adjusted operating margin above 25%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)